Radiation plus immunotherapy: a new hope for mesothelioma patients?
NCT ID NCT02959463
Summary
This early-stage trial is testing whether adding the immunotherapy drug pembrolizumab after radiation therapy is safe and tolerable for patients with malignant pleural mesothelioma who still have both lungs. The study aims to see if this combination helps the immune system better attack cancer cells that remain after radiation. Researchers will monitor side effects closely and track how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.